Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pierre Decazes

Showing results (41-50 of 55) with videos related to

Pageof 6
Sort By:
Hemasphere|January 30, 2023
Baseline <sup>18</sup>F-FDG Metabolic Tumor Volume Predicts Response to Rituximab Induction in Post-transplant Lymphoproliferative Disorders: A Multi-institutional Retrospective StudyDavid Morland, Lukshe Kanagaratnam, Fabrice Hubelé, et al.
Future Oncology (London, England)|February 10, 2025
Predictive factors of FOLFIRINOX chemotherapy toxicity in pancreatic adenocarcinoma patientsRoland Eid, Anthony Tarabay, Pierre Decazes, et al.
Clinical Nutrition ESPEN|May 18, 2023
High prevalence of pre-existing sarcopenia in critically ill patients with hematologic malignancies admitted to the intensive care unit for sepsis or septic shockAntoine Herault, Emilie Lévêque, Simon Draye-Carbonnier, et al.
Haematologica|February 22, 2020
Targeted genotyping of circulating tumor DNA for classical Hodgkin lymphoma monitoring: a prospective studyVincent Camus, Mathieu Viennot, Justine Lequesne, et al.
Blood Advances|August 31, 2022
A tumor volume and performance status model to predict outcome before treatment in diffuse large B-cell lymphomaCatherine Thieblemont, Loic Chartier, Ulrich Dührsen, et al.
Frontiers in Oncology|May 29, 2026
Predicting survival of patients treated with antibody-drug conjugates in early-phase clinical trials using AI-quantified 3D body composition on CT scansMatthieu Delaye, Littisha Lawrance, Younes Belkouchi, et al.
Hematological Oncology|July 12, 2025
Impact of Body Composition on Treatment Toxicity and Outcomes in Patients With Primary Mediastinal Large B-Cell LymphomaJuliette Penichoux, Pierre Decazes, Cédric Rossi, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|May 18, 2024
Trifluridine/tipiracil + oxaliplatin ± nivolumab vs FOLFOX ± nivolumab in HER2 negative advanced oesogastric adenocarcinoma: The PRODIGE73-UCGI40-LOGICAN trialDamien Botsen, Sylvie Chabaud, Hervé Perrier, et al.
Blood Advances|October 20, 2023
High PDL1/PDL2 gene expression correlates with worse outcome in primary mediastinal large B-cell lymphomaVincent Camus, Pierre-Julien Viailly, Fanny Drieux, et al.
Blood Advances|August 30, 2021
Outcomes after first-line immunochemotherapy for primary mediastinal B-cell lymphoma: a LYSA studyVincent Camus, Cédric Rossi, Pierre Sesques, et al.
Pageof 6

Showing results (41-50 of 55) with videos related to

Sort By:
Pageof 6
Hemasphere|January 30, 2023
Baseline <sup>18</sup>F-FDG Metabolic Tumor Volume Predicts Response to Rituximab Induction in Post-transplant Lymphoproliferative Disorders: A Multi-institutional Retrospective StudyDavid Morland, Lukshe Kanagaratnam, Fabrice Hubelé, et al.
Future Oncology (London, England)|February 10, 2025
Predictive factors of FOLFIRINOX chemotherapy toxicity in pancreatic adenocarcinoma patientsRoland Eid, Anthony Tarabay, Pierre Decazes, et al.
Clinical Nutrition ESPEN|May 18, 2023
High prevalence of pre-existing sarcopenia in critically ill patients with hematologic malignancies admitted to the intensive care unit for sepsis or septic shockAntoine Herault, Emilie Lévêque, Simon Draye-Carbonnier, et al.
Haematologica|February 22, 2020
Targeted genotyping of circulating tumor DNA for classical Hodgkin lymphoma monitoring: a prospective studyVincent Camus, Mathieu Viennot, Justine Lequesne, et al.
Blood Advances|August 31, 2022
A tumor volume and performance status model to predict outcome before treatment in diffuse large B-cell lymphomaCatherine Thieblemont, Loic Chartier, Ulrich Dührsen, et al.
Frontiers in Oncology|May 29, 2026
Predicting survival of patients treated with antibody-drug conjugates in early-phase clinical trials using AI-quantified 3D body composition on CT scansMatthieu Delaye, Littisha Lawrance, Younes Belkouchi, et al.
Hematological Oncology|July 12, 2025
Impact of Body Composition on Treatment Toxicity and Outcomes in Patients With Primary Mediastinal Large B-Cell LymphomaJuliette Penichoux, Pierre Decazes, Cédric Rossi, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|May 18, 2024
Trifluridine/tipiracil + oxaliplatin ± nivolumab vs FOLFOX ± nivolumab in HER2 negative advanced oesogastric adenocarcinoma: The PRODIGE73-UCGI40-LOGICAN trialDamien Botsen, Sylvie Chabaud, Hervé Perrier, et al.
Blood Advances|October 20, 2023
High PDL1/PDL2 gene expression correlates with worse outcome in primary mediastinal large B-cell lymphomaVincent Camus, Pierre-Julien Viailly, Fanny Drieux, et al.
Blood Advances|August 30, 2021
Outcomes after first-line immunochemotherapy for primary mediastinal B-cell lymphoma: a LYSA studyVincent Camus, Cédric Rossi, Pierre Sesques, et al.
Pageof 6